As of 2024-12-14, the Relative Valuation of Xvivo Perfusion AB (XVIVO.ST) is 170.02 SEK. This relative valuation is based on P/E multiples. With the latest stock price at 462.50 SEK, the upside of Xvivo Perfusion AB based on Relative Valuation is -63.2%.
The range of the Relative Valuation is 98.58 - 241.62 SEK.
| Range | Selected | |
| Trailing P/E multiples | 28.6x - 37.3x | 33.8x |
| Forward P/E multiples | 25.3x - 38.2x | 31.2x |
| Fair Price | 98.58 - 241.62 | 170.02 |
| Upside | -78.7% - -47.8% | -63.2% |
| Date | P/E |
| 2024-12-09 | 71.01 |
| 2024-12-06 | 71.78 |
| 2024-12-05 | 69.93 |
| 2024-12-04 | 72.01 |
| 2024-12-03 | 73.63 |
| 2024-12-02 | 75.41 |
| 2024-11-29 | 74.02 |
| 2024-11-28 | 72.86 |
| 2024-11-27 | 72.09 |
| 2024-11-26 | 70.55 |
| 2024-11-25 | 71.63 |
| 2024-11-22 | 69.62 |
| 2024-11-21 | 68.78 |
| 2024-11-20 | 68.93 |
| 2024-11-19 | 69.70 |
| 2024-11-18 | 68.62 |
| 2024-11-15 | 70.16 |
| 2024-11-14 | 72.01 |
| 2024-11-13 | 69.86 |
| 2024-11-12 | 69.78 |
| 2024-11-11 | 71.55 |
| 2024-11-08 | 69.47 |
| 2024-11-07 | 69.47 |
| 2024-11-06 | 68.78 |
| 2024-11-05 | 69.24 |
| 2024-11-04 | 69.47 |
| 2024-11-01 | 69.08 |
| 2024-10-31 | 69.39 |
| 2024-10-30 | 70.63 |
| 2024-10-29 | 71.24 |
| 2024-10-28 | 76.18 |
| 2024-10-25 | 73.79 |
| 2024-10-24 | 73.25 |
| 2024-10-23 | 75.25 |
| 2024-10-22 | 75.95 |
| 2024-10-21 | 77.57 |
| 2024-10-18 | 77.87 |
| 2024-10-17 | 77.57 |
| 2024-10-16 | 78.18 |
| 2024-10-15 | 77.87 |
| 2024-10-14 | 77.26 |
| 2024-10-11 | 77.72 |
| 2024-10-10 | 75.87 |
| 2024-10-09 | 78.49 |
| 2024-10-08 | 74.25 |
| 2024-10-07 | 74.17 |
| 2024-10-04 | 75.41 |
| 2024-10-03 | 76.87 |
| 2024-10-02 | 77.10 |
| 2024-10-01 | 77.57 |